LIFR Inhibitors
The chemical class of LIFR inhibitors encompasses a diverse group of compounds that intricately modulate LIFR activity through both direct and indirect mechanisms. Notable members of this class, such as AG-490, Tofacitinib, WP1066, Nifuroxazide, C188-9, Cryptotanshinone, WP1130, Pyrimethamine, NSC 348884, and SH-4-54, exert their influence by targeting the JAK/STAT pathway. This crucial signaling cascade is closely intertwined with LIFR activation, and these compounds, acting as JAK or STAT3 inhibitors, disrupt downstream events initiated by LIF binding. Consequently, they induce alterations in LIFR activity, impacting cellular responses associated with this intricate pathway. The unique case of Pyrvinium Pamoate introduces a distinct mechanism among LIFR inhibitors. Instead of directly targeting the JAK/STAT pathway, Pyrvinium Pamoate operates indirectly by modulating the Wnt/β-catenin pathway. This unconventional approach adds a layer of complexity to the spectrum of inhibitory actions within the chemical class, emphasizing the intricate interplay between different cellular pathways.
The chemical class of LIFR inhibitors, with its array of inhibitory mechanisms, highlights the complexity of cellular regulation and provides fertile ground for exploration. Understanding the nuanced interactions between inhibitors and cellular pathways is essential not only for unraveling the molecular intricacies of LIFR modulation but also for exploring strategies to fine-tune LIFR activity. The intricate cellular responses associated with LIFR dysregulation present a rich field for research, holding promise for both interventions and fundamental insights into cellular signaling networks. The exploration of LIFR inhibitors extends beyond the laboratory, offering a valuable resource that advances our comprehension of intricate cellular signaling networks. This chemical class not only sheds light on the molecular details of LIFR modulation but also holds implications for broader aspects of health and disease.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Tyrphostin B42 | 133550-30-8 | sc-3556 | 5 mg | $26.00 | 4 | |
AG-490 inhibits LIFR by targeting the JAK/STAT pathway. As a JAK2 inhibitor, it interferes with the phosphorylation cascade triggered by LIF binding, disrupting downstream signaling events. This inhibition downregulates LIFR activation, affecting cellular responses associated with LIFR-mediated pathways and providing insights into potential strategies for modulating LIFR activity. | ||||||
Stat3 Inhibitor III, WP1066 | 857064-38-1 | sc-203282 | 10 mg | $132.00 | 72 | |
WP1066 inhibits LIFR indirectly by targeting STAT3. As a STAT3 inhibitor, it disrupts the downstream events triggered by LIF binding, modulating cellular responses associated with LIFR-mediated pathways. This indirect inhibition sheds light on potential strategies for regulating LIFR activity through intervention in the JAK/STAT pathway, providing avenues for further exploration in cellular processes. | ||||||
Nifuroxazide | 965-52-6 | sc-204128 sc-204128A | 500 mg 5 g | $203.00 $520.00 | 5 | |
Nifuroxazide indirectly inhibits LIFR by impacting the JAK/STAT pathway. As a STAT3 inhibitor, it interferes with the signaling cascade initiated by LIF, leading to modulation of LIFR activity. This indirect inhibition suggests potential avenues for regulating LIFR-mediated processes through interventions in the JAK/STAT pathway, offering insights into cellular responses associated with LIFR dysregulation. | ||||||
Pyrvinium Pamoate | 3546-41-6 | sc-476920A sc-476920 | 250 mg 500 mg | $228.00 $422.00 | ||
Pyrvinium Pamoate indirectly inhibits LIFR through modulation of the Wnt/β-catenin pathway. By inhibiting the Wnt signaling pathway, it influences cellular processes connected to LIFR activity. This indirect inhibition offers potential avenues for regulating LIFR-mediated responses and provides insights into the crosstalk between different signaling pathways involved in LIFR modulation. | ||||||
Cryptotanshinone | 35825-57-1 | sc-280649 | 10 mg | $119.00 | 1 | |
Cryptotanshinone indirectly inhibits LIFR by impacting the JAK/STAT pathway. As a STAT3 inhibitor, it interferes with the signaling events triggered by LIF binding, leading to modulation of LIFR activity. This indirect inhibition suggests potential avenues for regulating LIFR-mediated processes through interventions in the JAK/STAT pathway, providing insights into cellular responses associated with LIFR dysregulation. | ||||||
WP1130 | 856243-80-6 | sc-364650 sc-364650A | 10 mg 50 mg | $490.00 $1484.00 | 1 | |
WP1130 inhibits LIFR indirectly by targeting the JAK/STAT pathway. As a deubiquitinase inhibitor, it modulates STAT3 activation, disrupting downstream signaling cascades initiated by LIF binding and leading to alterations in LIFR activity. This indirect inhibition provides insights into potential strategies for regulating LIFR-mediated processes through interventions in the JAK/STAT pathway, offering avenues for further exploration in cellular responses. | ||||||
Pyrimethamine | 58-14-0 | sc-208190 sc-208190A sc-208190B | 1 g 5 g 25 g | $80.00 $238.00 $825.00 | 5 | |
Pyrimethamine indirectly inhibits LIFR through modulation of the JAK/STAT pathway. By interfering with STAT3 activation, it disrupts downstream signaling events initiated by LIF binding, leading to alterations in LIFR activity. This indirect inhibition offers potential strategies for regulating LIFR-mediated processes through interventions in the JAK/STAT pathway, providing insights into cellular responses associated with LIFR dysregulation. | ||||||
NSC348884 | 81624-55-7 | sc-301483 sc-301483A | 5 mg 25 mg | $125.00 $480.00 | 2 | |
NSC 348884 inhibits LIFR indirectly by targeting the JAK/STAT pathway. As a STAT3 inhibitor, it interferes with the signaling cascade initiated by LIF, leading to modulation of LIFR activity. This indirect inhibition suggests potential avenues for regulating LIFR-mediated processes through interventions in the JAK/STAT pathway, providing insights into cellular responses associated with LIFR dysregulation. | ||||||